Please ensure Javascript is enabled for purposes of website accessibility

Cronos Group Sets Q3 Results Release Date

By Eric Volkman - Oct 12, 2019 at 8:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In about a month, we'll have the latest figures from the Canadian cannabis company.

Beaten-down marijuana stock Cronos Group (CRON -6.45%) has fixed the date for the unveiling of its latest quarterly results. 

The figures for the company's Q3 of fiscal 2019, which ended Sept. 30, will be revealed on Nov. 12. The company will also hold a conference call to discuss them beginning at 8:30 a.m. Eastern time that day. As is typical for such events, top managers will make presentations before opening the floor to questions -- of which there are bound to be at least a few.

Marijuana plant in growing facility.

Image source: Getty Images.

Cronos, like a high number of its peers in the cannabis industry, has seen its share price erode significantly of late. The stock has lost almost 50% of its value over the past three months, against the more or less flat-lining S&P 500 index. 

Much of this is due to investor worries about the general viability of the sector, which is struggling with numerous tough issues such as supply difficulties, the vaping crisis, a high level of competition, and the slow thawing of cannabis laws worldwide.

A clutch of recent analyst downgrades of the top marijuana stocks hasn't helped either; Cronos was one of several that had its price target cut by Jefferies in recent days. The investment bank still rates the stock an "underperform," and it knocked the price target down to $10 Canadian ($7.55) per share from the previous CA$15 ($11.33).

In all, expectations for Cronos have become more muted across the past few months. In April, analysts tracking the stock were collectively modeling nearly $143 million in sales for the company in its next fiscal year (2020). Earlier this month, that estimate had been whittled down to $110 million. As for Q3 estimates, they're a bit hard to come by; according to The Wall Street Journal, analysts are expecting a $0.02-per-share net loss.

Cronos suprised the market by posting bottom-line profits in each of its two most recently reported quarters. These, however, were greatly aided by one-off gains arising from the revalutation of derivative liabilities. Had it not been for these gains, which were sizable, Cronos would have been notably in the red.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Jefferies Financial Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
CRON
$3.19 (-6.45%) $0.22
Jefferies Financial Group Inc. Stock Quote
Jefferies Financial Group Inc.
JEF
$34.98 (0.26%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.